Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changsha
Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Changsha 37 Luoyang 4 Shenzhen 3 Shenyang 3 Guangzhou 3
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Xiangya Hospital of Central South University48 Second Xiangya Hospital of Central South University37 Eli Lilly and Company37 Janssen Research & Development, LLC31 Clear sponsor filter
Site location
Changsha37 Luoyang4 Shenzhen3 Shenyang3 Guangzhou3
All 25 locations
Target enrolment
to

Trials with a site in Changsha

37 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
NCT07795554Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
Second Xiangya Hospital of Central South University
Not applicable
60
Changsha
2026-11-01
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
30
Changsha
2026-10-01
Not yet open
Second Xiangya Hospital of Central South University
Not applicable
105
Changsha
2026-07
Not yet open
Second Xiangya Hospital of Central South University
Not applicable
60
Changsha
2026-06-02
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
9
Changsha
2026-06-01
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
18
Changsha
2026-05-29
Not yet open
Effects of Cofrogliptin on Beta-Cell Function in LADA Patients
NCT07460336Latent Autoimmune Diabetes in Adults (LADA)
DrugsCofrogliptin·Cholecalciferol·Metformin
Second Xiangya Hospital of Central South University
Not applicable
84
Changsha
2026-05-15
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
88
Changsha
2026-04-30
Not yet open
Second Xiangya Hospital of Central South University
Not applicable
472
Quanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changde, Changsha, Loudi
2026-04-18
Recruiting
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
Second Xiangya Hospital of Central South University
Observational
80
Changsha
2026-01-03
Recruiting
Second Xiangya Hospital of Central South University
Observational
2,950
Changsha
2025-10-27
Recruiting
Mobile Health and Wearable Devices for Diabetes Complication Management
NCT07129148Diabetes Mellitus Type 2, Diabetes Mellitus Complications
Second Xiangya Hospital of Central South University
Not applicable
6,000
Changsha
2025-10-01
Active, closed
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344Systemic Lupus Erythematosus
DrugCM355
Second Xiangya Hospital of Central South University
Not applicable
5
Changsha
2025-09-25
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2025-06-26
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2025-06-26
Recruiting
Interleukin-2 for Refractory Chronic Spontaneous Urticaria
NCT06924762Chronic Spontaneous Uriticaria
Second Xiangya Hospital of Central South University
Phase 2/3
124
Changsha
2025-03-19
Active, closed
Second Xiangya Hospital of Central South University
Observational
700
Changsha
2025-01-01
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Recruiting
Second Xiangya Hospital of Central South University
Phase 1
6
Changsha
2024-11-13
Recruiting
The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
NCT06975384Lung Cancer, Sleep Disturbance, Immune Checkpoint Inhibitors, Cancer, Treatment-Related
Second Xiangya Hospital of Central South University
Observational
1,270
Changsha
2024-11-01
Recruiting
Environmental Determinants of Type 1 Diabetes Risk
NCT07835724Type 1 Diabetes Mellitus (T1DM), Healthy Control, Relatives to/Carers of Patients
Second Xiangya Hospital of Central South University
Observational
11,240
Changsha
2024-08-01
Recruiting
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2024-04-20
Recruiting
Second Xiangya Hospital of Central South University
Observational
120,000
Changsha
2023-07-01
Recruiting
Second Xiangya Hospital of Central South University
Observational
200
Changsha
2023-05-01
Not yet open
Second Xiangya Hospital of Central South University
Observational
50
Changsha
2023-04
Recruiting
Second Xiangya Hospital of Central South University
Observational
50
Changsha
2023-03-23
Active, closed
Second Xiangya Hospital of Central South University
Observational
200
Changsha
2023-01-01
Recruiting
Multicenter Study of Fulminant Type 1 Diabetes in China
NCT05593081Diabetes Mellitus, Type 1
Second Xiangya Hospital of Central South University
Observational
240
Quanzhou, Guangzhou, Nanning, Zunyi, Haikou, Changsha, Yancheng, Nanchang
2022-05-20
Recruiting
Second Xiangya Hospital of Central South University
Observational
400
Changsha
2022-05-01
Not yet open
Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA
NCT04698330Type 1 Diabetes Mellitus, Autoimmune Diabetes
DrugBerberine
Second Xiangya Hospital of Central South University
Phase 4
240
Changsha
2022-05
Recruiting
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Recruiting
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
NCT05598528Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation, Primary Resistance
Second Xiangya Hospital of Central South University
Observational
210
Changsha
2021-09-28
Recruiting
Second Xiangya Hospital of Central South University
Observational
5,000
Changsha
2021-02-27
Recruiting
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
NCT05477979Lung Cancer, Psychological Stress, Immune Checkpoint Inhibitors, Cancer, Treatment-Related
Second Xiangya Hospital of Central South University
Observational
750
Changsha
2020-06-01
Recruiting
Second Xiangya Hospital of Central South University
Observational
500
Changsha
2016-09
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/changsha

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies with a site in Changsha that also match the filters currently applied.

How many clinical trials are recruiting in Changsha?

28 of the 37 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 6 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changsha), 37 studies
PhaseStudiesRecruitingShare
Observational171445.9%
Not applicable13835.1%
Phase 14410.8%
Phase 2112.7%
Phase 2/3112.7%
Phase 4102.7%

Most active sponsors

Lead sponsors with the most studies (Changsha)
Lead sponsorStudiesRecruiting
Second Xiangya Hospital of Central South University3728
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.